Breaking Tech Europe: Top 5 – SoftBank Leads $500m Into Agile Robots, Accel Backs Munich's SE3, and Vilnius' Biomatter Raises $18m

13/11/2026
17
AI-generated illustration of an industrial robot arm, a mapping drone, a map of Europe with glowing points and an enzyme molecule beside lab glassware

SoftBank and Nvidia put $500m into Munich's Agile Robots, Accel backs a TUM drone-software spin-out already deployed in Ukraine, and investors in Turin, Paris and Vilnius bet on measuring AI, predicting cancer trials and designing enzymes. Here are the five European tech stories that matter this morning.

1. Agile Robots raises $500m led by SoftBank at an $8.5bn valuation

Agile Robots (Munich) + SoftBank, Nvidia, Hitachi: $500m raised at an $8.5bn (€7.7bn) valuation, money earmarked for US expansion and more production in Germany.

The Munich-based maker of humanoid robots and robotic arms said on Thursday that the round was led by Japan's SoftBank, with Nvidia and Hitachi taking part, AFP reported. A spokesman told the agency that the company, founded in 2018, is now Europe's most valuable "physical AI" robotics firm. Founder and chief executive Zhaopeng Chen said the funds would support expansion in the United States, additional production capacity in Germany and entry into new markets. The company says it has deployed around 20,000 robots in automotive, consumer electronics and logistics, and that a factory it opened outside Munich this year can produce up to 10,000 humanoid robots a year. Those figures come from the company and have not been independently verified.

Why it matters: The round tests the argument that the continent's edge in AI lies in industrial deployment rather than frontier models, while Chinese rivals such as Unitree benefit from heavy state support.

Source: AFP via France 24

2. SE3 raises $30m from Accel five months after leaving stealth

SE3 (Munich, TUM spin-out) + Accel, Keen, Lakestar, Seedcamp: $30m Series A on top of a €5.5m seed, for software already running in Ukraine and on Bundeswehr contracts.

SE3 builds platform-agnostic "spatial intelligence" software that fuses feeds from drones and ground vehicles made by different manufacturers into a shared 3D picture, then coordinates the fleet on the edge, where electronic warfare can jam satellite navigation, according to TNW. The company says it is deployed in Ukraine, holds several contracts there and with Germany's Bundeswehr, and has shipped thousands of systems in two years. Its partners include HENSOLDT, Auterion and ERC System. The company spun out of Professor Daniel Cremers' computer-vision lab at the Technical University of Munich. The money will pay for new hires, a UK office and a bigger presence in Germany and Ukraine. From 2027 SE3 plans to move into robotics and emergency response.

Why it matters: European procurement is shifting towards modular, interoperable systems, which favours independent software layers over closed stacks from the big defence contractors. That makes SE3 a test case for whether that layer can become a business in its own right.

Source: TNW

3. Nebuly raises $21m to show boards what their AI agents are worth

Nebuly (Turin/New York) + Planven, Exor Ventures, CDP Venture Capital: $21m Series A to measure the business return on enterprise AI agents.

Planven led the round, with Exor Ventures, Tenacity Capital, TGVG Capital and Fastweb+Vodafone (via Founders Factory) taking part, Tech.eu reported. Italy's CDP Venture Capital invested through its Digital Transition Fund, which is backed by the EU's NextGenerationEU programme. Nebuly's platform analyses how employees and customers use AI agents, including tools built on Claude, ChatGPT and Microsoft Copilot. It estimates time saved and revenue influenced by AI, and it can run on-premises or in a customer's private cloud. Chief executive Francesco Signorato said companies are making hiring and headcount decisions "based on assumptions about AI productivity, not evidence". The funds go into sales teams in the US and Europe.

Why it matters: As AI budgets come under scrutiny from finance teams, tools that measure the return on AI spending are becoming a category of their own. Backing from Exor and CDP gives this Italian company a strong domestic base.

Source: Tech.eu

4. Orakl Oncology raises €30m to predict cancer-drug trial outcomes

Orakl Oncology (Paris) + Norrsken VC, Singular, Bpifrance: €30m ($34m) Series A, taking total funding to €45m, to forecast how cancer drugs will perform before clinical trials.

The French TechBio company combines AI with real patient biology to predict how oncology drugs will behave in trials, EU-Startups reported. Norrsken VC and Singular co-led the round. New investors include InfraVia Capital Partners, Serena, Bpifrance's Patient Autonome Fund, Teampact Ventures and Plug and Play, and existing backers Verve Ventures, Speedinvest and HCVC also took part. Orakl raised an €11m seed round led by Singular in December 2024. Chief executive Dr Fanny Jaulin said the money will extend the platform "across more cancer types and pharmaceutical programmes".

Why it matters: Orakl's pitch is to catch likely trial failures before they happen, and it joins a growing group of French AI-for-drug-discovery companies, including Rivercell and Generare, that raised capital this year.

Source: EU-Startups

5. Vilnius' Biomatter raises $18m for a new AI enzyme-design centre

Biomatter (Vilnius) + Astanor: $18m (€16.2m) Series A, its largest round yet, to build a 2,000 m² enzyme design and testing centre in Vilnius by 2027.

Lithuania's public broadcaster LRT, citing the BNS news agency, reported that Astanor led the round, with existing investors UVC Partners, Inventure and Metaplanet. Biomatter uses AI to design custom enzymes, including some for reactions with no natural equivalent. The company says it has delivered more than 50 enzymes to over 25 customers in Europe, the US and Japan, including AstraZeneca, BASF and Kirin Holdings. Roughly half its customers are in the US, where it will expand its commercial team. In a separate interview with chief executive and co-founder Laurynas Karpus, LRT.lt reported that the new centre could create 20 to 40 jobs. The company says it aims to cut design cycles from weeks to days.

Why it matters: The round keeps a Vilnius University spin-out's lab capacity in Lithuania while it chases US pharma and industrial customers. It is a notable signal for the Baltic biotech scene.

Source: LRT / BNS (Lithuanian)

Cover image: AI-generated illustration for EuropeanTechOnHeels; it does not depict real products, people or events.

Recent

Breaking Tech Europe: Top 5 – Genesis AI's $500m robot bet, Temu's DSA breach and 11 states' AI copyright push

Isomorphic Labs raises $5bn, Europe's biggest venture round, but its first AI-designed drug is still only heading for the clinic

A Responsible AI Governance Example for Europe

Breaking Tech Europe: Top 5 – Nokia-Led Group Bids for an EU AI Gigafactory, Orbify Beats Deloitte in Oslo, and Brussels Closes Data Talks With Kenya

Breaking Tech Europe: Top 5 – SoftBank Leads $500m Into Agile Robots, Accel Backs Munich's SE3, and Vilnius' Biomatter Raises $18m

13/11/2026
17
AI-generated illustration of an industrial robot arm, a mapping drone, a map of Europe with glowing points and an enzyme molecule beside lab glassware

SoftBank and Nvidia put $500m into Munich's Agile Robots, Accel backs a TUM drone-software spin-out already deployed in Ukraine, and investors in Turin, Paris and Vilnius bet on measuring AI, predicting cancer trials and designing enzymes. Here are the five European tech stories that matter this morning.

1. Agile Robots raises $500m led by SoftBank at an $8.5bn valuation

Agile Robots (Munich) + SoftBank, Nvidia, Hitachi: $500m raised at an $8.5bn (€7.7bn) valuation, money earmarked for US expansion and more production in Germany.

The Munich-based maker of humanoid robots and robotic arms said on Thursday that the round was led by Japan's SoftBank, with Nvidia and Hitachi taking part, AFP reported. A spokesman told the agency that the company, founded in 2018, is now Europe's most valuable "physical AI" robotics firm. Founder and chief executive Zhaopeng Chen said the funds would support expansion in the United States, additional production capacity in Germany and entry into new markets. The company says it has deployed around 20,000 robots in automotive, consumer electronics and logistics, and that a factory it opened outside Munich this year can produce up to 10,000 humanoid robots a year. Those figures come from the company and have not been independently verified.

Why it matters: The round tests the argument that the continent's edge in AI lies in industrial deployment rather than frontier models, while Chinese rivals such as Unitree benefit from heavy state support.

Source: AFP via France 24

2. SE3 raises $30m from Accel five months after leaving stealth

SE3 (Munich, TUM spin-out) + Accel, Keen, Lakestar, Seedcamp: $30m Series A on top of a €5.5m seed, for software already running in Ukraine and on Bundeswehr contracts.

SE3 builds platform-agnostic "spatial intelligence" software that fuses feeds from drones and ground vehicles made by different manufacturers into a shared 3D picture, then coordinates the fleet on the edge, where electronic warfare can jam satellite navigation, according to TNW. The company says it is deployed in Ukraine, holds several contracts there and with Germany's Bundeswehr, and has shipped thousands of systems in two years. Its partners include HENSOLDT, Auterion and ERC System. The company spun out of Professor Daniel Cremers' computer-vision lab at the Technical University of Munich. The money will pay for new hires, a UK office and a bigger presence in Germany and Ukraine. From 2027 SE3 plans to move into robotics and emergency response.

Why it matters: European procurement is shifting towards modular, interoperable systems, which favours independent software layers over closed stacks from the big defence contractors. That makes SE3 a test case for whether that layer can become a business in its own right.

Source: TNW

3. Nebuly raises $21m to show boards what their AI agents are worth

Nebuly (Turin/New York) + Planven, Exor Ventures, CDP Venture Capital: $21m Series A to measure the business return on enterprise AI agents.

Planven led the round, with Exor Ventures, Tenacity Capital, TGVG Capital and Fastweb+Vodafone (via Founders Factory) taking part, Tech.eu reported. Italy's CDP Venture Capital invested through its Digital Transition Fund, which is backed by the EU's NextGenerationEU programme. Nebuly's platform analyses how employees and customers use AI agents, including tools built on Claude, ChatGPT and Microsoft Copilot. It estimates time saved and revenue influenced by AI, and it can run on-premises or in a customer's private cloud. Chief executive Francesco Signorato said companies are making hiring and headcount decisions "based on assumptions about AI productivity, not evidence". The funds go into sales teams in the US and Europe.

Why it matters: As AI budgets come under scrutiny from finance teams, tools that measure the return on AI spending are becoming a category of their own. Backing from Exor and CDP gives this Italian company a strong domestic base.

Source: Tech.eu

4. Orakl Oncology raises €30m to predict cancer-drug trial outcomes

Orakl Oncology (Paris) + Norrsken VC, Singular, Bpifrance: €30m ($34m) Series A, taking total funding to €45m, to forecast how cancer drugs will perform before clinical trials.

The French TechBio company combines AI with real patient biology to predict how oncology drugs will behave in trials, EU-Startups reported. Norrsken VC and Singular co-led the round. New investors include InfraVia Capital Partners, Serena, Bpifrance's Patient Autonome Fund, Teampact Ventures and Plug and Play, and existing backers Verve Ventures, Speedinvest and HCVC also took part. Orakl raised an €11m seed round led by Singular in December 2024. Chief executive Dr Fanny Jaulin said the money will extend the platform "across more cancer types and pharmaceutical programmes".

Why it matters: Orakl's pitch is to catch likely trial failures before they happen, and it joins a growing group of French AI-for-drug-discovery companies, including Rivercell and Generare, that raised capital this year.

Source: EU-Startups

5. Vilnius' Biomatter raises $18m for a new AI enzyme-design centre

Biomatter (Vilnius) + Astanor: $18m (€16.2m) Series A, its largest round yet, to build a 2,000 m² enzyme design and testing centre in Vilnius by 2027.

Lithuania's public broadcaster LRT, citing the BNS news agency, reported that Astanor led the round, with existing investors UVC Partners, Inventure and Metaplanet. Biomatter uses AI to design custom enzymes, including some for reactions with no natural equivalent. The company says it has delivered more than 50 enzymes to over 25 customers in Europe, the US and Japan, including AstraZeneca, BASF and Kirin Holdings. Roughly half its customers are in the US, where it will expand its commercial team. In a separate interview with chief executive and co-founder Laurynas Karpus, LRT.lt reported that the new centre could create 20 to 40 jobs. The company says it aims to cut design cycles from weeks to days.

Why it matters: The round keeps a Vilnius University spin-out's lab capacity in Lithuania while it chases US pharma and industrial customers. It is a notable signal for the Baltic biotech scene.

Source: LRT / BNS (Lithuanian)

Cover image: AI-generated illustration for EuropeanTechOnHeels; it does not depict real products, people or events.

Recent

© European Tech On Heels - 2026
Made with
Web Wings